Kenvue Inc. (KVUE) Stock Analysis
Range Bound setup
Consumer Defensive · Household & Personal Products
Sell if holding. Analyst target reached at $17.38 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk).
Kenvue is a consumer health company with $15.1B net sales in fiscal 2025, owning brands in Self Care (Tylenol, Zyrtec), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (BAND-AID, Listerine). A pending merger with Kimberly-Clark received shareholder approval in... Read more
Sell if holding. Analyst target reached at $17.38 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk). Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-12Item 5.02HIGHCFO Amit Banati notified Company of intent to step down effective May 12, 2026 to become CEO of another company. Company indicated it would appoint an interim CFO; no specific successor named at time of filing.SEC filing →
- 2026-02-17Item 2.05MEDIUMBoard approved restructuring initiative February 17, 2026. Costs associated with exit or disposal activities (Our Vue Forward restructuring program).SEC filing →
- 2026-04-15Item 5.02MEDIUMHeather Howlett (current Chief Accounting Officer) appointed interim CFO and Chief Accounting Officer effective May 12, 2026, succeeding departing CFO Amit Banati. Monthly stipend of $125,000 during interim role.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $17.38 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 6 days (event risk). Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $16.75. Score 5.0/10, moderate confidence.
Take-profit target: $17.47 (+0.6% upside). Prior stop was $16.75. Stop-loss: $16.75.
Analyst target reached - limited upside remaining; Earnings in 6 days (event risk); Negative news sentiment (-0.67).
Kenvue Inc. trades at a P/E of 23.1 (forward 14.6). TrendMatrix value score: 5.9/10. Verdict: Sell.
20 analysts cover KVUE with a consensus score of 2.8/5. Average price target: $20.
What does Kenvue Inc. do?Kenvue is a consumer health company with $15.1B net sales in fiscal 2025, owning brands in Self Care (Tylenol, Zyrtec),...
Kenvue is a consumer health company with $15.1B net sales in fiscal 2025, owning brands in Self Care (Tylenol, Zyrtec), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (BAND-AID, Listerine). A pending merger with Kimberly-Clark received shareholder approval in January 2026.